"We have to get prices down for a lot of reasons. We have no choice. For Medicare, for Medicaid, we have to get the prices way down so that's what we're gonna be talking about," Trump told a group of CEOs from the pharma sector.
He assured the companies of streamlining the process and end their years of wait to get drugs approved.
"The US drug companies have produced extraordinary results for our country, but the pricing has been astronomical for our country. Gonna do better," Trump said.
"Accelerating cures... Focused on accelerating FDA approvals. We're gonna get the approval process much faster," he said.
As such he promised to change a lot of the rules.
"We're going to be ending global freeloading. Foreign price controls reduce the resources of American drug companies to finance drug and R&D innovation. I think you people know that very well. Very unfair to this country," Trump said.
"Our trade policy will prioritise that foreign countries pay their fair share for US-manufactured drugs so our drug companies have greater financial resources to accelerate the development of new cures. And I think it's so important. But right now, it's very unfair what other countries are doing to us," he added.
"A lot of it has to do with the fact that other countries take advantage of us with their money and their money supply and devaluation because we don't know anything -- our country has been run so badly, we know nothing about devaluation. Every other country lives on devaluation," he said.
"Our trade policy will prioritise that foreign countries pay their fair share for US manufactured drugs so our drug companies have greater financial resources to accelerate the development of new cures," Trump said.
"A lot of that has to do with regulation, a lot of it has to do with the fact that other countries take advantage of ours with their money and their money supply and devaluation," the US President said.
"Because our country has been run so badly, we know nothing about devaluation. You look at Japan. They play the money market, they play the devaluation market, while we sit here like a bunch of dummies," he said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
